6 results on '"Van Den Neste, Eric"'
Number of results to display per page
Search Results
2. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
- Author
-
Houot, Roch, Cartron, Guillaume, Bijou, Fontanet, de Guibert, Sophie, Salles, Gilles A., Fruchart, Christophe, Bouabdallah, Krimo, Maerevoet, Marie, Feugier, Pierre, Le Gouill, Steven, Tilly, Hervé, Casasnovas, Rene-Olivier, Moluçon-Chabrot, Cécile, Van Den Neste, Eric, Zachee, Pierre, Andre, Marc, Bonnet, Christophe, Haioun, Corinne, Van Hoof, Achiel, Van Eygen, Koen, Molina, Lysiane, Nicolas-Virelizier, Emmanuelle, Ruminy, Philippe, and Morschhauser, Franck
- Published
- 2019
- Full Text
- View/download PDF
3. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
- Author
-
Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
0301 basic medicine ,Male ,cd52 expression ,Cancer Research ,epstein-barr-virus ,medicine.medical_treatment ,CHOP ,Gastroenterology ,PROPHYLAXIS ,0302 clinical medicine ,Cause of Death ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Significant risk ,Alemtuzumab ,ComputingMilieux_MISCELLANEOUS ,Aged, 80 and over ,Hematology ,lymphoproliferative disorders ,Hazard ratio ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Middle Aged ,CHEMOTHERAPY ,Prognosis ,3. Good health ,Treatment Outcome ,Oncology ,Vincristine ,030220 oncology & carcinogenesis ,Toxicity ,PHASE-II ,Female ,medicine.drug ,medicine.medical_specialty ,prognostic-factors ,Medication Adherence ,03 medical and health sciences ,SDG 3 - Good Health and Well-being ,Internal medicine ,Humans ,non-hodgkin-lymphoma ,Cyclophosphamide ,Aged ,Chemotherapy ,therapy ,business.industry ,Lymphoma, T-Cell, Peripheral ,DETUDE-DES-LYMPHOMES ,medicine.disease ,Survival Analysis ,Peripheral T-cell lymphoma ,030104 developmental biology ,Doxorubicin ,Prednisone ,business - Abstract
PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.
- Published
- 2021
- Full Text
- View/download PDF
4. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
- Author
-
Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Neoplasm, Residual ,MESH: Immunotherapy ,Chronic lymphocytic leukemia ,Gastroenterology ,MESH: Clinical Trials, Phase III as Topic ,0302 clinical medicine ,Bone Marrow ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,MESH: Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Aged ,education.field_of_study ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,MESH: Follow-Up Studies ,Prognosis ,3. Good health ,Fludarabine ,Survival Rate ,Leukemia ,MESH: Antineoplastic Combined Chemotherapy Protocols ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,MESH: Vidarabine ,MESH: Bone Marrow ,Female ,MESH: Rituximab ,Immunotherapy ,Rituximab ,MESH: Clinical Trials, Phase II as Topic ,Vidarabine ,medicine.drug ,medicine.medical_specialty ,Cyclophosphamide ,MESH: Survival Rate ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH: Prognosis ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,Chemoimmunotherapy ,Internal medicine ,medicine ,Humans ,education ,Survival rate ,MESH: Neoplasm, Residual ,Aged ,Retrospective Studies ,MESH: Humans ,business.industry ,MESH: Cyclophosphamide ,MESH: Retrospective Studies ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Male ,body regions ,030104 developmental biology ,Clinical Trials, Phase III as Topic ,Bone marrow ,business ,MESH: Female ,Follow-Up Studies - Abstract
International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD
- Published
- 2020
- Full Text
- View/download PDF
5. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
- Author
-
Houot, Roch, primary, Cartron, Guillaume, additional, Bijou, Fontanet, additional, de Guibert, Sophie, additional, Salles, Gilles A., additional, Fruchart, Christophe, additional, Bouabdallah, Krimo, additional, Maerevoet, Marie, additional, Feugier, Pierre, additional, Le Gouill, Steven, additional, Tilly, Hervé, additional, Casasnovas, Rene-Olivier, additional, Moluçon-Chabrot, Cécile, additional, Van Den Neste, Eric, additional, Zachee, Pierre, additional, Andre, Marc, additional, Bonnet, Christophe, additional, Haioun, Corinne, additional, Van Hoof, Achiel, additional, Van Eygen, Koen, additional, Molina, Lysiane, additional, Nicolas-Virelizier, Emmanuelle, additional, Ruminy, Philippe, additional, and Morschhauser, Franck, additional
- Published
- 2018
- Full Text
- View/download PDF
6. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
- Author
-
Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, and Cymbalista, Florence
- Abstract
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10−5) MRD assessment using flow cytometry, in blood (N= 401) and bone marrow (N= 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p= 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p< 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.